 JERSEY CITY, N.J., April 30, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, presented posters on two data sets from the Companys Phase 3 VANISH Program demonstrating the therapeutic potential of ibrexafungerp Brexafemme as a treatment for vulvovaginal candidiasis VVC, also known as vaginal yeast infection, at the 2021 American College of Obstetricians and Gynecologists ACOG Annual Meeting, taking place virtually from April 30 May 2, 2021. 